X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ASTRAZENECA PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ASTRAZENECA PHARMA CIPLA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 33.3 391.7 8.5% View Chart
P/BV x 2.9 19.2 15.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 CIPLA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-18
ASTRAZENECA PHARMA
Mar-14
CIPLA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6631,285 51.6%   
Low Rs479634 75.6%   
Sales per share (Unadj.) Rs189.0189.6 99.7%  
Earnings per share (Unadj.) Rs17.6-0.2 -8,641.7%  
Cash flow per share (Unadj.) Rs34.03.8 885.0%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs176.768.6 257.5%  
Shares outstanding (eoy) m805.1225.00 3,220.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.1 59.7%   
Avg P/E ratio x32.5-4,712.7 -0.7%  
P/CF ratio (eoy) x16.8249.6 6.7%  
Price / Book Value ratio x3.214.0 23.1%  
Dividend payout %17.10-   
Avg Mkt Cap Rs m459,72423,988 1,916.5%   
No. of employees `00023.61.6 1,514.4%   
Total wages/salary Rs m26,9011,605 1,676.5%   
Avg. sales/employee Rs Th6,446.13,040.2 212.0%   
Avg. wages/employee Rs Th1,139.41,029.2 110.7%   
Avg. net profit/employee Rs Th600.0-3.3 -18,376.8%   
INCOME DATA
Net Sales Rs m152,1934,740 3,211.0%  
Other income Rs m3,57792 3,883.3%   
Total revenues Rs m155,7694,832 3,223.8%   
Gross profit Rs m28,264-130 -21,774.9%  
Depreciation Rs m13,228101 13,071.3%   
Interest Rs m1,1420-   
Profit before tax Rs m17,470-139 -12,577.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-775139 -558.1%   
Tax Rs m2,5015 49,137.5%   
Profit after tax Rs m14,166-5 -278,304.5%  
Gross profit margin %18.6-2.7 -678.1%  
Effective tax rate %14.3-3.7 -390.7%   
Net profit margin %9.3-0.1 -8,667.2%  
BALANCE SHEET DATA
Current assets Rs m108,1412,726 3,966.4%   
Current liabilities Rs m38,3222,435 1,573.8%   
Net working cap to sales %45.96.1 746.2%  
Current ratio x2.81.1 252.0%  
Inventory Days Days9774 131.5%  
Debtors Days Days7441 182.5%  
Net fixed assets Rs m109,4111,035 10,568.1%   
Share capital Rs m1,61050 3,220.4%   
"Free" reserves Rs m140,682942 14,928.0%   
Net worth Rs m142,2921,716 8,292.1%   
Long term debt Rs m36,6210-   
Total assets Rs m228,6064,156 5,500.6%  
Interest coverage x16.3NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.1 58.4%   
Return on assets %6.7-0.1 -5,467.5%  
Return on equity %10.0-0.3 -3,356.3%  
Return on capital %10.00-  
Exports to sales %32.85.7 574.9%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs m49,883270 18,461.4%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m51,691375 13,799.0%   
Fx outflow Rs m21,033470 4,473.7%   
Net fx Rs m30,658-96 -32,085.4%   
CASH FLOW
From Operations Rs m14,628-8 -180,587.7%  
From Investments Rs m-8,540-146 5,861.4%  
From Financial Activity Rs m-3,855862 -447.1%  
Net Cashflow Rs m2,431709 343.1%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 0.3 4,066.7%  
FIIs % 23.7 15.7 151.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 9.1 287.9%  
Shareholders   161,166 12,856 1,253.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks ahead of Election Results; Realty Stocks Plummet(Closing)

Indian share markets settled around 2% lower today following a sell-off in the global markets and due to uncertainty over the outcome of state assembly elections tomorrow.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Dec 10, 2018 (Close)

TRACK CIPLA

CIPLA - DIVIS LABORATORIES COMPARISON

COMPARE CIPLA WITH

MARKET STATS